Japan
8 Vaccines Approved for Use in Japan
RNA
Takeda
TAK-919 (Moderna formulation)
Approved in 1 country
2 trials in 1 country
Approval Source: takeda.com
RNA
Pfizer/BioNTech
Comirnaty
Approved in 149 countries
100 trials in 31 countries
Approval Source: japantimes.co.jp
Non Replicating Viral Vector
Oxford/AstraZeneca
Vaxzevria
Approved in 149 countries
73 trials in 34 countries
Approval Source: astrazeneca.com
Protein Subunit
Takeda
TAK-019 (Novavax formulation)
Approved in 1 country
3 trials in 1 country
Approval Source: reuters.com
RNA
Moderna
Spikevax Bivalent Original/Omicron BA.1
Approved in 38 countries
5 trials in 4 countries
Approval Source: stockhouse.com
RNA
Pfizer/BioNTech
Comirnaty Bivalent Original/Omicron BA.1
Approved in 35 countries
3 trials in 5 countries
Approval Source: bloomberg.com
RNA
Pfizer/BioNTech
Comirnaty Bivalent Original/Omicron BA.4/BA.5
Approved in 33 countries
4 trials in 1 country
Approval Source: english.kyodonews.net
RNA
Moderna
Spikevax Bivalent Original/Omicron BA.4/BA.5
Approved in 33 countries
2 trials in 1 country
Approval Source: english.kyodonews.net
15 in Clinical Trials in Japan
Protein Subunit
Shionogi
S-268019
9 trials in 2 countries
VLP
Medicago
Covifenz
Approved in 1 country
6 trials in 6 countries
DNA
AnGes
AG0302-COVID19
8 trials in 1 country
RNA
Daiichi Sankyo Co Ltd
DS-5670a
5 trials in 1 country
RNA
Moderna
Spikevax
Approved in 88 countries
70 trials in 24 countries
RNA
Pfizer/BioNTech
Comirnaty
Approved in 149 countries
100 trials in 31 countries
Non Replicating Viral Vector
Janssen (Johnson & Johnson)
Ad26.COV2.S
Approved in 111 countries
23 trials in 23 countries
Non Replicating Viral Vector
Oxford/AstraZeneca
Vaxzevria
Approved in 149 countries
73 trials in 34 countries
Inactivated
KM Biologics Co Ltd
KD-414
7 trials in 2 countries
Protein Subunit
Takeda
TAK-019 (Novavax formulation)
Approved in 1 country
3 trials in 1 country
DNA
AnGes
AG0301-COVID19
2 trials in 1 country
RNA
Elixirgen Therapeutics Inc
EXG-5003
2 trials in 1 country
RNA
Takeda
TAK-919 (Moderna formulation)
Approved in 1 country
2 trials in 1 country
RNA
VLP Therapeutics Japan
VLPCOV-01
Non Replicating Viral Vector
Janssen (Johnson & Johnson)
Jcovden
Approved in 113 countries
26 trials in 25 countries